Effect of Rifabutin in Dolutegravir Dosing: A Case Series

Background: Tuberculosis (TB) is the leading cause of death in human immunodeficiency virus (HIV)-infected people worldwide. Currently there are no studies examining the use of Rifabutin (RBN) and Dolutegravir (DTG) in co-infected persons. This is a case series of 4 co-infected patients receiving bo...

Descripción completa

Detalles Bibliográficos
Autores principales: Mendoza, Maria A., Alshaer, Mohammad H., Roldan, Giovanni, Castro, Jose Guillermo, Ashkin, David, Peloquin, Charles A., Boulanger, Catherine V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9421219/
https://www.ncbi.nlm.nih.gov/pubmed/36026587
http://dx.doi.org/10.1177/23259582221111077

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9421219/
https://www.ncbi.nlm.nih.gov/pubmed/36026587
http://dx.doi.org/10.1177/23259582221111077

Ejemplares similares